Skip to main content
Equibles
GOSS logo

GOSS · Gossamer Bio, Inc. · Webcasts, Transcripts & Audio

Track GOSS — free

Use GOSS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GOSS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.71 -0.22 (-2.01%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company's existing cash and cash equivalents are not sufficient to fund operating plans for at least one year from the issuance date of these financial statements. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$66.85M
Shares
6.11M
Volume · Oct 2 236.38K Avg daily vol (16 sessions) 345.74K

Gossamer Bio, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Gossamer Bio, Inc. (GOSS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$42.50M '23 Q2 23-08-08 · $9.89M −$36.64M '25 Q1 25-05-15 ▲71.5% $16.95M −$46.66M '26 Q1 26-05-18 LATEST ▼19.6% $9.24M $16.90M '26 Q2 26-07-27
Earnings call
FY26 · Q2
2026-07-27
Gossamer Bio, Inc. (GOSS) Q2 2026 Earnings Call Transcript
Confident tone Saralutinib clinical evidence FDA regulatory path and NDA submission PHILD indication expansion
Revenue
$9.24M
▼ 19.6% YoY
Diluted EPS
$-6.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-18
Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call Transcript
Positive tone CT-FRI sub-study and reverse remodeling Procera Phase III results and clinical signal Confirmatory evidence from TORI Phase II
Revenue
$16.95M
▲ 71.5% YoY
Diluted EPS
$-16.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Call Transcript
Confident tone Seralutinib commercial opportunity PROSERA Phase III enrollment Competitive landscape (sotatercept, Tyvaso)
Revenue
$9.89M
Diluted EPS
$-12.80
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Gossamer Bio, Inc. (GOSS) Q2 2023 Earnings Call
Revenue
$
Diluted EPS
$-36.00
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-03
Gossamer Bio, Inc. (GOSS) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Gossamer Bio, Inc. (GOSS) Q3 2021 Earnings Call Transcript
Diluted EPS
$-64.00
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Gossamer Bio, Inc. (GOSS) Q2 2021 Earnings Call Transcript
Diluted EPS
$-64.00
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Gossamer Bio, Inc. (GOSS) Q1 2021 Earnings Call
Diluted EPS
$-62.40
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Gossamer Bio, Inc. (GOSS) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Gossamer Bio, Inc. (GOSS) Q3 2020 Earnings Call Transcript
Diluted EPS
$-64.00
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Gossamer Bio, Inc. (GOSS) Q1 2020 Earnings Call Transcript
Diluted EPS
$-69.60
Audio Transcript Slides 8-K10-Q
Showing 1–11 of 11 webcasts
Key facts CIK 1728117 CUSIP 38341P102 13F (30d) 4 filings 4 filers Visit website